Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD and Food Effect of Golcadomide in Healthy Participants
NCT05350800Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2022
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of golcadomide in non-Hodgkin lymphoma (NHL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and 1 more (3 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Maximum observed plasma concentration at Day 1, Time of maximum observed plasma concentration at Day 1 and 1 more. Started Sep 2022; status: completed.
02
Drugs
golcadomide
03
Conditions
non-Hodgkin lymphoma (NHL)diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)T-cell lymphoma
Beyond the preview
Go deeper on NCT05350800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05350800.